source
- Lilly reports 79% response rate for FRα-directed ADC in platinum-sensitive ovarian cancerLilly presented phase 1 data on its FRα‑directed antibody‑drug conjugate, sofetabart mipitecan (Sofe-M), combined with bevacizumab in patients whose ovarian cancer had progressed after platinum the…
- EyePoint cuts half its staff and ends wet AMD trials after second Phase 3 failure, pivots to diabetic macular edemaEyePoint said it is launching a strategic review after its investigational drug duravyu failed another Phase 3 study in wet age‑related macular degeneration. The company reported that the top‑line…